MX2022014871A - Composiciones y metodos para inducir arni o ifn tipo i en celulas competentes de ifn y usos de los mismos. - Google Patents

Composiciones y metodos para inducir arni o ifn tipo i en celulas competentes de ifn y usos de los mismos.

Info

Publication number
MX2022014871A
MX2022014871A MX2022014871A MX2022014871A MX2022014871A MX 2022014871 A MX2022014871 A MX 2022014871A MX 2022014871 A MX2022014871 A MX 2022014871A MX 2022014871 A MX2022014871 A MX 2022014871A MX 2022014871 A MX2022014871 A MX 2022014871A
Authority
MX
Mexico
Prior art keywords
ifn
subject
methods
compositions
type
Prior art date
Application number
MX2022014871A
Other languages
English (en)
Inventor
Stephanie Dewitte-Orr
Original Assignee
Wilfrid Laurier Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilfrid Laurier Univ filed Critical Wilfrid Laurier Univ
Publication of MX2022014871A publication Critical patent/MX2022014871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)

Abstract

Se proporciona un compuesto de ARN de doble cadena (ARNdc) que comprende una hebra guía y una hebra pasajera, la hebra guía y la hebra pasajera tienen una longitud de al menos 300 pares de bases (pb) cada una, la hebra guía comprende un segmento complementario a una secuencia de ácido nucleico diana de un transcrito de un gen diana. También se proporcionan métodos para silenciar el transcrito de un gen diana en una célula de vertebrados o en un sujeto vertebrado, para tratar una infección patógena en un sujeto y para reducir la replicación o infectividad de una infección patógena en la célula de vertebrados o en el sujeto vertebrado, respectivamente, que comprenden la administración al sujeto o a la célula de un compuesto, vector, conjugado o composición de ARNdcc aquí divulgados.
MX2022014871A 2020-05-25 2021-05-25 Composiciones y metodos para inducir arni o ifn tipo i en celulas competentes de ifn y usos de los mismos. MX2022014871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063029632P 2020-05-25 2020-05-25
PCT/CA2021/050703 WO2021237344A1 (en) 2020-05-25 2021-05-25 Compositions and methods of inducing rnai or type i ifn in ifn competent cells and uses thereof

Publications (1)

Publication Number Publication Date
MX2022014871A true MX2022014871A (es) 2023-03-09

Family

ID=78745690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014871A MX2022014871A (es) 2020-05-25 2021-05-25 Composiciones y metodos para inducir arni o ifn tipo i en celulas competentes de ifn y usos de los mismos.

Country Status (7)

Country Link
US (1) US20230212581A1 (es)
EP (1) EP4158027A4 (es)
JP (1) JP2023527935A (es)
AU (1) AU2021280414A1 (es)
CA (1) CA3178673A1 (es)
MX (1) MX2022014871A (es)
WO (1) WO2021237344A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070118315A (ko) * 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
AU2003258100A1 (en) * 2002-08-06 2004-02-23 Intradigm Corporation Methods of down regulating target gene expression in vivo by introduction of interfering rna
US7927792B2 (en) * 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
JP4753130B2 (ja) * 2003-12-12 2011-08-24 独立行政法人産業技術総合研究所 インターフェロン応答が軽減された長い干渉用二重鎖ｒｎａ
EP1789447B1 (en) * 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Method of delivering rna interference and uses thereof
CN107129957A (zh) * 2007-06-29 2017-09-05 北京强新生物科技有限公司 促使长dsRNA可用于哺乳动物和其他所选动物细胞中的基因寻靶
EP2555778A4 (en) * 2010-04-06 2014-05-21 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
AU2012332517B9 (en) * 2011-11-03 2017-08-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
WO2017136895A1 (en) * 2016-02-10 2017-08-17 Queensland University Of Technology Constructs and methods for conferring virus resistance
US10630062B2 (en) * 2017-02-24 2020-04-21 Ripley Tools, Llc Adjustable wire stripper

Also Published As

Publication number Publication date
AU2021280414A1 (en) 2022-12-08
JP2023527935A (ja) 2023-06-30
EP4158027A1 (en) 2023-04-05
WO2021237344A1 (en) 2021-12-02
US20230212581A1 (en) 2023-07-06
CA3178673A1 (en) 2021-12-02
EP4158027A4 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
EP4137161A1 (en) Method and drug for treating hurler syndrome
EP1214945B1 (de) Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2008283975A5 (es)
SG11202111401RA (en) Methods and compositions for editing rnas
CN107177598B (zh) 用于抑制BIRC5靶基因mRNA表达的寡核酸分子及其成套组合物
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
EP2773760B2 (en) Double-stranded rna for immunostimulation
JP2022511550A5 (es)
JP2009514877A5 (es)
JP2018526986A5 (es)
IL315613A (en) MAPT siRNA AND USES THEREOF
PE20241479A1 (es) Agentes de interferencia de arn de mapt
JP2024520429A (ja) 操作されたガイドｒｎａ及びポリヌクレオチド
MX2024000650A (es) Acido nucleico, composicion y conjugado que contiene el mismo, y metodo de preparacion y uso.
MX2022014871A (es) Composiciones y metodos para inducir arni o ifn tipo i en celulas competentes de ifn y usos de los mismos.
Tsai et al. Complete sequence and structure of ribosomal RNA gene of Heterosporis anguillarum
JP2023506842A5 (es)
CN111378656B (zh) 一种抑制埃博拉病毒的核酸、含有该核酸的药物组合物及其用途
CN105002214B (zh) 用于载体表达的复合多联gRNA和RNAi的表达框架
MX2025006656A (es) Oligonucleotidos antisentido para el tratamiento de enfermedades cardiovasculares
Kamen et al. Orientation of the complementary strands of polyoma virus DNA with respect to the DNA physical map
WO2024211376A3 (en) Compositions and methods for treating cag repeat diseases
EA200500873A1 (ru) Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита
JP7807019B2 (ja) 新規なレプリカーゼサイクリング反応（ｒｃｒ）
BR112023018284A2 (pt) Estratégias para knock-ins em locais de porto seguro c3